RxDoctor Payments Data

Robert Sammartino, DO

Neurology · Sewell, NJNPI 1336247451

Payments from drug & device makers

$59,871in general payments, 2019–2025

Across 1,209 payments — averaging $49.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$46K
  • UCB, Inc.$1K
  • Biogen$1K
  • EMD Serono, Inc.$1K
  • Pfizer$835
  • Teva Pharmaceuticals USA, Inc.$690
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$42,35671%
  • Travel & lodging$1510%
  • Food & beverage$17,03628%
  • Education$3271%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)316$45,726
UCB, Inc.126$1,197
Biogen81$1,147
EMD Serono, Inc.65$1,014
Pfizer58$835
Teva Pharmaceuticals USA, Inc.33$690
Lilly USA, LLC35$573
Argenx US, Inc.19$491
AstraZeneca(2 entities)21$432
MDD US Operations, LLC17$416
Novartis28$409
Eisai Inc.20$396
Neurocrine Biosciences, Inc.20$394
Amneal Pharmaceuticals LLC26$382
Bristol Myers Squibb24$341
Neurelis, Inc.22$320
Johnson & Johnson(2 entities)15$278
Kyowa Kirin, Inc.20$270
SK Life Science, Inc.17$267
Amgen(2 entities)9$263
Sunovion Pharmaceuticals Inc.12$231
Biohaven Pharmaceutical Holding Company Ltd.19$227
E.r. Squibb & Sons, L.L.C.7$211
Lundbeck LLC13$211
Otsuka America Pharmaceutical, Inc.13$205
Abbott6$202
Takeda Pharmaceuticals U.S.A., Inc.11$200
Arbor Pharmaceuticals, Inc.12$181
Biohaven Pharmaceuticals, Inc.15$177
Stryker1$164
W. L. Gore & Associates, Inc.11$162
Boston Scientific7$142
Genentech USA, Inc.7$123
Acorda Therapeutics, Inc8$118
Supernus Pharmaceuticals, Inc.7$105
Catalyst Pharmaceuticals, Inc.6$95
Acadia Pharmaceuticals Inc6$89
Axsome Therapeutics, Inc.5$85
Adamas Pharmaceuticals, Inc.6$81
Impel Pharmaceuticals Inc.4$71
Merz Pharmaceuticals, LLC4$61
Sumitomo Pharma America, Inc.4$61
Medtronic1$61
GE HealthCare4$60
Avion Pharmaceuticals4$54
Impel Pharmaceuticals LLC3$54
Vanda Pharmaceuticals Inc.3$48
Azurity Pharmaceuticals, Inc.3$47
Banner Life Sciences, LLC3$46
Tanabe Pharma America, Inc.3$39
Avanir Pharmaceuticals, Inc.3$38
Scilex Pharmaceuticals Inc.2$34
Livanova USA, Inc.2$34
Aucta Pharmaceuticals, Inc.2$30
Octapharma USA, Inc.2$27
Grifols USA, LLC2$27
Upsher-smith Laboratories LLC2$25
Corium, LLC2$24
Sanofi2$24
Genentech, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,871 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$192,287
Medicare patients
583
Services billed
1,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz12$453,707
BriviactBrivaracetam70$90,854
CopaxoneGlatiramer Acetate12$83,661
Nurtec OdtRimegepant Sulfate34$71,467
UbrelvyUbrogepant51$67,059
Oxtellar XrOxcarbazepine31$64,860
RexultiBrexpiprazole39$52,384
QuliptaAtogepant35$52,240
RytaryCarbidopa/Levodopa63$44,884
Teriflunomide13$38,061
NourianzIstradefylline17$36,316
Galantamine Hbr398$35,790
Memantine Hcl791$32,971
TrintellixVortioxetine Hydrobromide25$24,323
BotoxOnabotulinumtoxina18$22,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$432$453,70712 claims
AbbVieUbrelvy, Qulipta, Botox$45,726$142,046104 claims
UCB, Inc.Briviact, Neupro$1,197$102,85782 claims
Teva Pharmaceuticals USA, Inc.Copaxone$690$83,66112 claims
PfizerNurtec Odt$835$71,46734 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$105$64,86031 claims
Otsuka America Pharmaceutical, Inc.Rexulti$205$52,38439 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$382$46,92789 claims
Kyowa Kirin, Inc.Nourianz$270$36,31617 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$200$24,32325 claims
Neurelis, Inc.Valtoco$320$18,45613 claims
Arbor Pharmaceuticals, Inc.Horizant$181$18,15915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 521 neurology providers in New Jersey.

Other neurology in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →